ArticleExperimental dermatology2010
The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.
Article in Experimental dermatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Vitamin D and the aging skin: insights into oxidative stress, inflammation, and barrier function.Immunity & ageing : I & A · 2025Review
- Current Molecular Markers of Melanoma and Treatment Targets.International journal of molecular sciences · 2020Review
- The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions.The Journal of steroid biochemistry and molecular biology · 2014Review
- Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.Drug metabolism and disposition: the biological fate of chemicals · 2013Article
- Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression.Human pathology · 2013Article
- Rat CYP24A1 acts on 20-hydroxyvitamin D(3) producing hydroxylated products with increased biological activity.Biochemical pharmacology · 2012Article
- Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes.Anticancer research · 2012Article
- New vitamin D analogs as potential therapeutics in melanoma.Expert review of anticancer therapy · 2012Review
- Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system.Advances in anatomy, embryology, and cell biology · 2012Review
- High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.British journal of cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Hormonally active vitamin D3, 1,25-(OH)2D3, is believed to have a role in the prevention of cancer formation and in limiting the aggressiveness of cancers that do arise. Therefore,much interest is presently being focused on 1,25-(OH)2D3 and its analogues as potential treatments for various cancers including melanoma. This article discusses the evidence in favour of a role for 1,25-(OH)2D3 in protection against the progression of melanocytic lesions and also summarizes the mechanisms by which 1,25-(OH)2D3 may act to protect against melanoma development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.